Genetically encoded elastin-like polypeptide nanoparticles for drug delivery.

Joshua J Milligan, Soumen Saha, Irene C Jenkins, Ashutosh Chilkoti

Journal: Current opinion in biotechnology 2022;74():146-153

PMID: 34920210

Full Text on Elsevier Science View on PubMed

Abstract

Small molecule drugs suffer from poor in vivo half-life, rapid degradation, and systemic off-target toxicity. To address these issues, researchers have developed nanoparticles that significantly enhance the delivery of many drugs while reducing their toxicity and improving targeting to specific organs. Recombinantly synthesized biomaterials such as elastin-like polypeptides (ELPs) have unique attributes that greatly facilitate the rational design of nanoparticles for drug delivery. These attributes include biocompatibility, precise control over amino acid sequence design, and stimuli-responsive self-assembly into nanostructures that can be loaded with a range of drugs to enhance their pharmacokinetics and pharmacodynamics, significantly improving their therapeutic efficacy over the free drugs. This review summarizes recent developments in genetically encoded, self-assembling ELP nanoparticles and their applications for drug delivery.

Address: Department of Biomedical Engineering, Duke University, Durham, NC 277018, USA.; Department of Biomedical Engineering, Duke University, Durham, NC 277018, USA. Electronic address: [email protected].

DOI: 10.1016/j.copbio.2021.11.006

Link outs

Subscription / membership required

Full Text Sources:

MeSH Terms: Amino Acid Sequence, Drug Delivery Systems, Elastin, Nanoparticles, Peptides